Metformin Plus Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer

Affiliations

¹ The Medical Department, 3D Medicines Inc, Shanghai, China.
² Department of Respiratory Medicine, Daping Hospital, Army Medical University, Chongqing, China.

Comment

Chan Gao et al. JAMA Oncol. 2020.

. 2020 May 1;6(5):782.

doi: 10.1001/jamaoncol.2020.0059.

¹ The Medical Department, 3D Medicines Inc, Shanghai, China.
² Department of Respiratory Medicine, Daping Hospital, Army Medical University, Chongqing, China.

No abstract available

Comment in

Metformin Plus Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer-Reply.
Arrieta O, Ramirez-Tirado LA, Zatarain-Barrón ZL. Arrieta O, et al. JAMA Oncol. 2020 May 1;6(5):782-783. doi: 10.1001/jamaoncol.2020.0062. JAMA Oncol. 2020. PMID: 32163099 No abstract available.

Effect of Metformin Plus Tyrosine Kinase Inhibitors Compared With Tyrosine Kinase Inhibitors Alone in Patients With Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Phase 2 Randomized Clinical Trial.
Arrieta O, Barrón F, Padilla MS, Avilés-Salas A, Ramírez-Tirado LA, Arguelles Jiménez MJ, Vergara E, Zatarain-Barrón ZL, Hernández-Pedro N, Cardona AF, Cruz-Rico G, Barrios-Bernal P, Yamamoto Ramos M, Rosell R. Arrieta O, et al. JAMA Oncol. 2019 Nov 1;5(11):e192553. doi: 10.1001/jamaoncol.2019.2553. Epub 2019 Nov 14. JAMA Oncol. 2019. PMID: 31486833 Free PMC article.